In the GeparQuinto trial , 1,948 patients were randomized to receive four cycles epirubicin/cyclophosphamide ( EC , 90/600mg/m ( 2 ) q3w ) followed by four cycles docetaxel ( D , 100mg/m ( 2 ) q3w ) each with ( ECB-DB ) or without ( EC-D ) bevacizumab ( B , 15mg/kg q3w ) concurrent with chemotherapy .